Sea Mild Biotechnology Co., Ltd.
Sea Mild Biotechnology Co., Ltd. manufactures and sells paints, coatings, and detergents in Taiwan. It offers laundry, household, and personal detergent, as well as epidemic prevention products under the Sea Mild Biotech brand name. The company was established in 2007 is headquartered in Taoyuan City, Taiwan.
Sea Mild Biotechnology Co., Ltd. (7516) - Total Liabilities
Latest total liabilities as of June 2025: NT$174.29 Million TWD
Based on the latest financial reports, Sea Mild Biotechnology Co., Ltd. (7516) has total liabilities worth NT$174.29 Million TWD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Sea Mild Biotechnology Co., Ltd. - Total Liabilities Trend (2016–2024)
This chart illustrates how Sea Mild Biotechnology Co., Ltd.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Sea Mild Biotechnology Co., Ltd. Competitors by Total Liabilities
The table below lists competitors of Sea Mild Biotechnology Co., Ltd. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Eastern Technical Engineering Public Company Limited
BK:ETE
|
Thailand | ฿1.40 Billion |
|
Liberty Star Uranium & Metals Corp
OTCQB:LBSR
|
USA | $1.79 Million |
|
Stria Lithium Inc
PINK:SRCAF
|
USA | $49.48K |
|
DCM Limited
NSE:DCM
|
India | ₹829.90 Million |
|
Vicarious Surgical Inc.
NYSE:RBOT
|
USA | $15.26 Million |
|
ZECON Bhd
KLSE:7028
|
Malaysia | RM1.42 Billion |
|
Blaize Holdings, Inc. Warrants
NASDAQ:BZAIW
|
USA | $59.60 Million |
Liability Composition Analysis (2016–2024)
This chart breaks down Sea Mild Biotechnology Co., Ltd.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.52 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.62 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.62 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Sea Mild Biotechnology Co., Ltd.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Sea Mild Biotechnology Co., Ltd. (2016–2024)
The table below shows the annual total liabilities of Sea Mild Biotechnology Co., Ltd. from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$153.71 Million | +28.14% |
| 2023-12-31 | NT$119.96 Million | +28.70% |
| 2022-12-31 | NT$93.21 Million | +13.09% |
| 2021-12-31 | NT$82.41 Million | -25.87% |
| 2020-12-31 | NT$111.18 Million | -34.94% |
| 2019-12-31 | NT$170.89 Million | +54.32% |
| 2018-12-31 | NT$110.73 Million | -41.98% |
| 2017-12-31 | NT$190.85 Million | +0.23% |
| 2016-12-31 | NT$190.40 Million | -- |